Stockscreener 앱 받기
3.35
0.00%
0.00
Newcelx Ltd 주식(NCEL)의 최신 뉴스
NewcelX Ltd (NCEL) Shareholders to Sell 694,000 Shares Amid Unpr - GuruFocus
NewcelX Ltd (NCEL) Pulls Back 2.54% as Shares Test Near-Term Support at $3.10Wyckoff Upthrust - Vinanet
NewcelX Ord Shs (NCEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NewcelX appoints diabetes researcher Ricordi to advisory board By Investing.com - Investing.com Nigeria
NewcelX (NCEL) Slides 6.2% to $3.34, Testing Key Support Near $3.17Diagonal Spread Trade - vinanet.vn
NewcelX Ltd. (NCEL) Rises 3.83% to $3.49, Testing Key Resistance at $3.66Fear Greed Extreme - dars.gov.et
Press Release: NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing - Moomoo
NewcelX Announces $1.4 Million Private Placement at 20% Premium to Market to Advance NCEL-101 for Type 1 Diabetes - Quiver Quantitative
NewcelX Ltd. (NCEL) Edges Higher as Stock Tests Key Resistance at $3.70Post-Earnings Moves - dars.gov.et
NewcelX Ord Shs (NCEL) Valuation: PE, PB & Fair Value Analysis - TradingKey
NewcelX Ord Shs (NCEL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NewcelX Ord Shs (NCEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NewcelX Ord Shs (NCEL) Income Statement - TradingKey
NewcelX Ord Shs (NCEL) Balance Sheet - TradingKey
NewcelX Ord Shs (NCEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NewcelX Ord Shs (NCEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NewcelX Ord Shs (NCEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NCEL|NewcelX Ord Shs|Price:3.755|Chg%:-0.070 - TradingKey
NewcelX Ord Shs (NCEL) Cash Flow - TradingKey
NewcelX Ltd. Revenue Breakdown – NASDAQ:NCEL - TradingView
NewcelX (NCEL) Secures Patent for Innovative Technology - GuruFocus
NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio - The Manila Times
NewcelX Ltd. (NCEL) Holds Near $3.98 Support Zone After Modest DeclineRip Sell Trade - dars.gov.et
Laidlaw Initiates NewcelX(NCEL.US) With Buy Rating, Announces Target Price $23 - Moomoo
NCEL Initiated Coverage by Laidlaw & Co. -- Price Target Announced at $23 - GuruFocus
Laidlaw initiates NewcelX stock with buy rating on diabetes therapy - Investing.com
NLSP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
NewcelX Strengthens Diabetes Push With Appointment of Leading Transplant Pioneer Camillo Ricordi - TipRanks
NewcelX appoints diabetes researcher Ricordi to advisory board - Investing.com
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board - The Manila Times
NewcelX appoints diabetes research pioneer Dr. Camillo Ricordi to boost Type 1 diabetes therapy development. - Pluang
NewcelX Appoints Diabetes Research Leader Camillo Ricordi to Scientific Advisory Board Following FDA Pre-IND Milestone - Quiver Quantitative
Enterprise value to EBIT forward of NewcelX Ltd. – BOATS:NCEL - TradingView
Enterprise value to revenue forward of NewcelX Ltd. – NASDAQ:NCEL - TradingView
Enterprise value to EBITDA forward of NewcelX Ltd. – NASDAQ:NCEL - TradingView
NCELNewcelX Ltd Volatility & Greeks - Finviz
NewcelX Ltd. (NCEL) Holds Steady at $3.85 as Traders Eye Key ResistanceInsider Buying Alerts - dars.gov.et
Price to book forward of NewcelX Ltd. – NASDAQ:NCEL - TradingView
NCEL Should I Buy - Intellectia AI
Newcelx Announces Successful FDA Pre-Ind Meet - Moomoo
NewcelX Wins FDA Backing to Advance NCEL-101 Toward Type 1 Diabetes Trials - The Globe and Mail
NewcelX receives FDA feedback on type 1 diabetes therapy plan - Investing.com
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes - The Manila Times
NewcelX receives FDA feedback on type 1 diabetes therapy plan By Investing.com - Investing.com India
NewcelX Announces Successful FDA Pre-IND Meeting for NCEL-101 Type 1 Diabetes Program - Quiver Quantitative
NewcelX Ltd. Announces Successful FDA Pre-IND Meeting With Clear Path Forward For NCEL-101 Toward Starting Clinical Trials For Type 1 Diabetes - marketscreener.com
NewcelX Ltd. (NCEL) Gains 2.72%: Approaching Key Resistance at $3.96Key Reversal Day - dars.gov.et
NewcelX Shareholders Approve All Proposals at June 30 Annual Meeting - TipRanks
Number of shareholders of NewcelX Ltd. – NASDAQ:NCEL - TradingView
Number of shareholders of NewcelX Ltd. – BOATS:NCEL - TradingView
NewcelX Ltd. Actuals & Estimates (NASDAQ:NCEL) - TradingView
NewcelX Ord Shs (NCEL) Institutional Confidence - TradingKey
[EFFECT] NewcelX Ltd. SEC Filing - Stock Titan
NewcelX Ord Shs (NCEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
0.86%
0.31%
자본화:
|
볼륨(24시간):